offline
Merck (MRK) Beats on Q4 Earnings, Plans Women Health Spin Off
...Merck & Co., Inc. reported fourth-quarter 2019 adjusted earnings of $1.16 per share, which beat the Zacks Consensus Estimate of $1.14. Earnings rose 12% year over year. ...
...Revenues rose 8% year over year (9% excluding currency impact) to $11.9 billion, which missed the Zacks Consensus Estimate of $12.1 billion. Along with the earnings release, Merck announced that it will spin off products from its Women’s Health unit, legacy drugs (including Zetia and Vytorin) and biosimilar products into a new publicly traded company. ...
https://www.zacks.com/stock/news/750517/...quote_news
...Merck & Co., Inc. reported fourth-quarter 2019 adjusted earnings of $1.16 per share, which beat the Zacks Consensus Estimate of $1.14. Earnings rose 12% year over year. ...
...Revenues rose 8% year over year (9% excluding currency impact) to $11.9 billion, which missed the Zacks Consensus Estimate of $12.1 billion. Along with the earnings release, Merck announced that it will spin off products from its Women’s Health unit, legacy drugs (including Zetia and Vytorin) and biosimilar products into a new publicly traded company. ...
https://www.zacks.com/stock/news/750517/...quote_news
__________________
Don't stop to think, have another drink. (The Kinks, When Work is Over)
